VANTAA, Finland, November 12, 2014 /PRNewswire/ --
Usefulness of Oscare SonoTMfor assessment of osteoporosis validated in clinical studies
Oscare Medical Oy announces that it will be demonstrating its novel low-frequency ultrasound device, the OsCare SonoTM for osteoporosis assessment, at this year's Medica in Hall 16, booth E57. Medica, the world's largest medical exhibition, will be held on 12th - 15th November in Dusseldorf, Germany.
Osteoporosis, a bone condition that incurs an increasing risk of fracture, is a rapidly increasing problem for aging societies. Recent studies have questioned the effectiveness of current screening guidelines and called for better early screening tools. X-ray-based methods are the gold standard for confirming a diagnosis of osteoporosis, but the expense and the exposure to ionizing radiation mean X-ray techniques are impractical for community care. Quantitative ultrasound (QUS) methods are now generating renewed interest.
A novel QUS device, the OsCare SonoTMassesses bone strength in the forearm radial bone. By using very low frequency ultrasound, measurement results correlate with bone cortical thickness, bone elasticity and bone mineral density (BMD), including BMD of the deeper cortical layers - suggesting OsCare SonoTM offers enhanced sensitivity to early osteoporotic changes. The OsCare SonoTM device offers a convenient way of assessing skeletal bone health and is a promising new screening tool for identifying people at an increased relative risk for osteoporosis and, potentially, bone fractures.
About Oscare SonoTM
The Oscare SonoTM is a compact, hand-held device designed for use in clinics and low-threshold locations, such as high street pharmacies. The device itself attaches via a USB connector to a standard PC. A measurement is taken from the forearm over a few minutes using harmless ultrasound. Proprietary algorithms compensate for the effects of soft tissues. An individual's measurement is compared to the normal value observed in healthy young women, and the final Oscare SonoTM result is ready within seconds for counseling.
About Oscare Medical
Oscare Medical was founded in 2007 to commercialize the results of a decade of research into bone health at the University of Jyväskylä, Finland. Since 2013, Oscare Medical has been majority-owned by Nasdaq-OMX-listed Revenio Group Corp and is now part of the Revenio Health Tech segment which includes the hugely successful Icare® tonometer product family. The Oscare SonoTM is CE-marked and is already on sale in several European countries. Oscare Medical is now rapidly expanding its distribution partner network. See: http://www.oscaremedical.com .
Sales & Marketing Manager
SOURCE Oscare Medical